Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/27/2024 | $170.00 → $194.00 | Outperform | Raymond James |
11/6/2024 | $170.00 | Mkt Perform → Outperform | Raymond James |
6/3/2024 | $126.00 → $160.00 | Neutral → Overweight | Piper Sandler |
4/15/2024 | $148.00 → $170.00 | Hold → Buy | Stifel |
3/25/2024 | $117.00 → $160.00 | Equal Weight → Overweight | Wells Fargo |
1/30/2024 | $107.00 → $121.00 | Buy → Hold | Jefferies |
1/3/2024 | Buy → Hold | Needham | |
11/8/2023 | Outperform → Mkt Perform | Raymond James |
8-K - MASIMO CORP (0000937556) (Filer)
8-K - MASIMO CORP (0000937556) (Filer)
8-K - MASIMO CORP (0000937556) (Filer)
Strategic integration of Sound United's award-winning audio brands strengthens HARMAN's product portfolio and propels business growth HARMAN International ("HARMAN"), a wholly-owned subsidiary of Samsung Electronics Co., Ltd., focused on connected technologies for automotive, consumer, and enterprise markets, today announced it has completed the acquisition of Sound United, the former consumer audio business of Masimo Corporation (NASDAQ:MASI). Sound United's portfolio of iconic audio brands includes Bowers & Wilkins, Denon, Marantz, Definitive Technology, Polk Audio, HEOS, Classé, and Boston Acoustics. This press release features multimedia. View the full release here: https://www.busin
Masimo (NASDAQ:MASI) today announced it has completed the previously announced sale of its Sound United consumer audio business to HARMAN International ("HARMAN"), a wholly-owned subsidiary of Samsung Electronics Co., Ltd. Katie Szyman, Chief Executive Officer of Masimo, stated, "The completion of the Sound United sale is an important milestone in our ongoing efforts to focus on our core professional healthcare business. With this chapter behind us, we are even better positioned to broaden Masimo's patient impact, accelerate growth, and deliver stronger margins. We have exciting opportunities ahead, and I am confident that we will be able to continue building on our positive momentum to d
Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ:MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/Continuous Patient Monitoring with Masim
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
3 - MASIMO CORP (0000937556) (Issuer)
Raymond James reiterated coverage of Masimo with a rating of Outperform and set a new price target of $194.00 from $170.00 previously
Raymond James upgraded Masimo from Mkt Perform to Outperform and set a new price target of $170.00
Piper Sandler upgraded Masimo from Neutral to Overweight and set a new price target of $160.00 from $126.00 previously
American Heart Association Consortium Advances Development of Evidence-based Health Tech Solutions Masimo (NASDAQ:MASI), a global medical technology company that develops and manufactures innovative noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708674775/en/Masimo is a member of the American Heart Association's Innovators' Network The Innovators' N
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid
Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman
Strategic integration of Sound United's award-winning audio brands strengthens HARMAN's product portfolio and propels business growth HARMAN International ("HARMAN"), a wholly-owned subsidiary of Samsung Electronics Co., Ltd., focused on connected technologies for automotive, consumer, and enterprise markets, today announced it has completed the acquisition of Sound United, the former consumer audio business of Masimo Corporation (NASDAQ:MASI). Sound United's portfolio of iconic audio brands includes Bowers & Wilkins, Denon, Marantz, Definitive Technology, Polk Audio, HEOS, Classé, and Boston Acoustics. This press release features multimedia. View the full release here: https://www.busin
Masimo Corporation (NASDAQ:MASI) today announced its financial results for the second quarter ended June 28, 2025. Second Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $371 million, representing 8% growth on a reported basis; Non-GAAP revenue of $370 million, representing 7% growth on a constant currency basis(2); GAAP net income per diluted share of $0.82; and Non-GAAP net income per diluted share(2) of $1.33, which grew 46% versus prior year period. Katie Szyman, Chief Executive Officer of Masimo, said, "We once again delivered strong results in the second quarter as our core health care business continued to demonstrate strong growth and earnings. W
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release second quarter 2025 financial results for the period ended June 28, 2025, after the market closes on Tuesday, August 5, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered partic
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)